Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22135752 | 1.00 | CYP2D6 (0.55) | CYP2D6KCNH2CHRM4DRD2HTR7 | |
| SCHEMBL22135732 | 0.89 | CYP2D6 (0.55) | CYP2D6KCNH2ALDH1A1GAACASP6 | |
| SCHEMBL22135730 | 0.89 | CYP2D6 (0.55) | CYP2D6KCNH2ALDH1A1GAACASP6 | |
| SCHEMBL22135757 | 0.87 | CYP2D6 (0.58) | CYP2D6KCNH2GAACASP6DHODH | |
| SCHEMBL4191954 | 0.86 | CYP2D6 (0.70) | CYP2D6KCNH2GAACASP6DHODH | |
| SCHEMBL30455081 | 0.86 | CYP2D6 (0.70) | CYP2D6KCNH2GAACASP6DHODH | |
| SCHEMBL22135733 | 0.86 | CYP2D6 (0.70) | CYP2D6KCNH2GAACASP6DHODH | |
| SCHEMBL22118714 | 0.85 | CYP2D6 (0.52) | CYP2D6KCNH2GAACASP6DHODH | |
| SCHEMBL22135801 | 0.85 | CYP2D6 (0.52) | CYP2D6KCNH2GAACASP6DHODH | |
| SCHEMBL29478217 | 0.85 | CYP2D6 (0.52) | CYP2D6KCNH2GAACASP6DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114173780-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| WO-2020131573-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NUREDIS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RTCB, RRM2B | CYP2D6 3475/4885KCNH2 4714/4885CHRM4 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.